Joshua A. Linscott

Featured in: Favicon

onclive.com Favicon

europeanurology.com

Articles

FGFR Inhibition in Urothelial Carcinoma

Sep 30, 2024 | europeanurology.com | Roger Li |Joshua A. Linscott |James Catto |Joshua J. Meeks |Siamak Daneshmand |Bishoy M Faltas | +4 more

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAbDepartment of Immunology, H.
Dr Linscott on the Use of Urinary Cell-free Tumor DNA to Predict MRD in High-Risk NMIBC

Sep 10, 2024 | onclive.com | Joshua A. Linscott

CommentaryVideoSeptember 10, 2024Author(s):Joshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.
Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

Aug 23, 2024 | onclive.com | Joshua A. Linscott

CommentaryVideoAugust 23, 2024Author(s):Fact checked by:Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC. Joshua Linscott, MD, PhD, urologic oncology fellow, Moffitt Cancer Center, discusses the rationale for a study evaluating a urinary cell-free tumor DNA (utDNA) assay for minimal residual disease (MRD) detection in patients with high-risk non–muscle-invasive bladder cancer (NMIBC).
Dr Linscott on Future Directions for utDNA Research in Bladder Cancer

Aug 8, 2024 | onclive.com | Joshua A. Linscott

Joshua Linscott, MD, PhD, urologic oncology fellow, Moffitt Cancer Center, discusses the use of tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease (MRD) prior to standard repeat transurethral resection of bladder tumors (rTURBT) in high-risk non–muscle-invasive bladder cancer (NMIBC). A study enrolled and collected urine samples from 53 patients with high-risk NMIBC prior to undergoing rTURBT.
Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC

Jun 25, 2024 | onclive.com | Joshua A. Linscott

Joshua Linscott, MD, PhD, urologic onologist, Moffitt Cancer Center, discusses findings from a study investigating the use of urinary cell-free tumor DNA (utDNA) to predict minimal residual disease (MRD) prior to repeat transurethral resection of bladder tumors (rTURBT) in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The study investigated the efficacy of using tumor fraction and copy number burden (CNB) from utDNA as biomarkers for detecting MRD.